265 related articles for article (PubMed ID: 31332935)
1. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria.
Sinn DH; Kim SE; Kim BK; Kim JH; Choi MS
J Viral Hepat; 2019 Dec; 26(12):1465-1472. PubMed ID: 31332935
[TBL] [Abstract][Full Text] [Related]
2. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
[TBL] [Abstract][Full Text] [Related]
3. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.
Lin D; Yang HI; Nguyen N; Hoang J; Kim Y; Vu V; Le A; Chaung K; Nguyen V; Trinh H; Li J; Zhang J; Hsing A; Chen CJ; Nguyen MH
Aliment Pharmacol Ther; 2016 Oct; 44(8):846-55. PubMed ID: 27549411
[TBL] [Abstract][Full Text] [Related]
4. Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus is equivalent between genotype B and C in long term.
Haga H; Saito T; Okumoto K; Tomita K; Katsumi T; Mizuno K; Nishina T; Watanabe H; Ueno Y
J Viral Hepat; 2019 Jul; 26(7):866-872. PubMed ID: 30924226
[TBL] [Abstract][Full Text] [Related]
5. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
6. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B.
Lee J; Yoo SH; Sohn W; Kim HW; Choi YS; Won JH; Heo JY; Park SJ; Park YM
Clin Mol Hepatol; 2016 Sep; 22(3):339-349. PubMed ID: 27729627
[TBL] [Abstract][Full Text] [Related]
7. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
[TBL] [Abstract][Full Text] [Related]
8. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Yakushijin T; Iio S; Doi Y; Yamada A; Kaneko A; Hagiwara H; Mita E; Oshita M; Itoh T; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
J Gastroenterol; 2015 Jul; 50(7):785-94. PubMed ID: 25384794
[TBL] [Abstract][Full Text] [Related]
9. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
10. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
11. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
12. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.
Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M;
Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395
[TBL] [Abstract][Full Text] [Related]
13. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
15. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis.
Lin CW; Lin CC; Mo LR; Chang CY; Perng DS; Hsu CC; Lo GH; Chen YS; Yen YC; Hu JT; Yu ML; Lee PH; Lin JT; Yang SS
J Hepatol; 2013 Apr; 58(4):730-5. PubMed ID: 23220252
[TBL] [Abstract][Full Text] [Related]
16. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
[TBL] [Abstract][Full Text] [Related]
20. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.
Kim EJ; Yeon JE; Kwon OS; Lee HN; Shin SK; Kang SH; Byun KS; Kim JH; Kwon SY; Suh SJ; Yim HJ; Kim YS; Kim JH
Dig Dis Sci; 2017 Mar; 62(3):808-816. PubMed ID: 28035553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
